{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:15:08Z","timestamp":1792782908272,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10-44066"],"award-info":[{"award-number":["U10-44066"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10-180868"],"award-info":[{"award-number":["U10-180868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pharmacia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10549-021-06417-y","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T09:03:48Z","timestamp":1651568628000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)"],"prefix":"10.1007","volume":"193","clinical-trial-number":[{"clinical-trial-number":"nct00087178","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-151X","authenticated-orcid":false,"suffix":"Jr.","given":"Charles E.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bandos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Robidoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Polikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H. G.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Carolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Baez-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios P.","family":"Mamounas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wolmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"issue":"9","key":"6417_CR1","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1200\/JCO.1990.8.9.1483","volume":"8","author":"B Fisher","year":"1990","unstructured":"Fisher B, Brown AM, Dimitrov NV et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8(9):1483\u20131496","journal-title":"J Clin Oncol"},{"issue":"4","key":"6417_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1200\/JCO.2001.19.4.931","volume":"19","author":"B Fisher","year":"2001","unstructured":"Fisher B, Anderson S, Tan-Chiu E et al (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19(4):931\u2013942. https:\/\/doi.org\/10.1200\/JCO.2001.19.4.931","journal-title":"J Clin Oncol"},{"issue":"33","key":"6417_CR3","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.1200\/JCO.2005.08.071","volume":"23","author":"LF Hutchins","year":"2005","unstructured":"Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23(33):8313\u20138321","journal-title":"J Clin Oncol"},{"issue":"22","key":"6417_CR4","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1200\/JCO.2005.09.423","volume":"23","author":"MN Levine","year":"2005","unstructured":"Levine MN, Pritchard KI, Bramwell VH et al (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22):5166\u20135170","journal-title":"J Clin Oncol"},{"issue":"2","key":"6417_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2003.04.148","volume":"21","author":"P Fumoleau","year":"2003","unstructured":"Fumoleau P, Kerbrat P, Romestaing P et al (2003) Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21(2):298\u2013305","journal-title":"J Clin Oncol"},{"issue":"12","key":"6417_CR6","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1200\/JCO.2005.05.059","volume":"23","author":"J Bonneterre","year":"2005","unstructured":"Bonneterre J, Roch\u00e9 H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23(12):2686\u20132693","journal-title":"J Clin Oncol"},{"key":"6417_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/bjc.1978.124","volume":"37","author":"SJ White","year":"1978","unstructured":"White SJ, Freedman LS (1978) Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 37:849\u2013857","journal-title":"Br J Cancer"},{"key":"6417_CR8","doi-asserted-by":"publisher","unstructured":"Ganz PA, Bandos H, Geyer CE Jr, et al (2022) Behavioral and health outcomes from the NRG Oncology\/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Res Treat. 192(1):153\u2013161. https:\/\/doi.org\/10.1007\/s10549-021-06475-2. Epub 2022 Feb 3. PMID: 35112166. https:\/\/pubmed.ncbi.nlm.nih.gov\/35112166\/","DOI":"10.1007\/s10549-021-06475-2"},{"key":"6417_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","volume":"80","author":"DY Lin","year":"1993","unstructured":"Lin DY, Wei LJ, Ying Z (1993) Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80:557\u2013572","journal-title":"Biometrika"},{"key":"6417_CR10","doi-asserted-by":"crossref","unstructured":"Jacobs SA, Wilson JW, Bandos H, et al. NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. Cancer Res 75 (9); SABCS 2014 December 9\u201313, 2015; San Antonio, TX. Abstr S3\u201302.","DOI":"10.1158\/1538-7445.SABCS14-S3-02"},{"issue":"23","key":"6417_CR11","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/jnci\/92.23.1870","volume":"92","author":"C McNeil","year":"2000","unstructured":"McNeil C (2000) Consensus panel endorses range of adjuvant therapies for breast cancer. J Natl Cancer Inst 92(23):1870. https:\/\/doi.org\/10.1093\/jnci\/92.23.1870","journal-title":"J Natl Cancer Inst"},{"key":"6417_CR12","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726\u20133734","journal-title":"J Clin Oncol"},{"key":"6417_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF et al (2018) Adjuvant chemotherapy guided by a 21-Gene Expression Assay in breast cancer. N Engl J Med 379:111\u2013121","journal-title":"N Engl J Med"},{"key":"6417_CR14","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F ,van't Veer LJ (2016) Bogaerts J (2016) MINDACT Investigators: 70-Gene Signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717\u2013729","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s10549-022-06613-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06417-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T03:25:59Z","timestamp":1675481159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6417"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06417-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10549-022-06613-4","URL":"https:\/\/doi.org\/10.1007\/s10549-022-06613-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Charles E. Geyer, Jr.\u2014Grants, non-financial support and other from Genentech\/Roche, Daiichi\/Sankyo, and AstraZeneca, during the conduct of the study, and personal fees from Exact Sciences and Athenex, outside the submitted work. Priya Rastogi: Genentech\/Roche\u2014Unpaid advisory boards, travel, accommodations; Lilly\u2014Travel, accommodations; Astra\/Zeneca\u2014Travel, accommodations. Johnathan Polikoff \u2013 Consultant, Natera. Louise Provencher: Consulting or Advisory Role:\u00a0Lilly, Pfizer, Roche, Novartis; Research Funding: Pfizer, Roche, Novartis, Merck, GlaxoSmithKline, Odonate Therapeutics Sandra M. Swain: Personal Fees\u00a0for consulting\/advisory services\/nonpromotional speaking: Astra-Zeneca,\u00a0Athenex, Daiichi-Sankyo, Genentech\/Roche, Exact Sciences (Genomic Health), Eli Lilly and Company,\u00a0Bejing\u00a0Medical Award\u00a0Association, Merck, Natera, Molecular Templates, Silverback Therapeutics; Non-financial support (i.e., travel, accommodations, and\/or food & beverage); Genentech\/Roche: Research support (to institution): Genentech\/Roche,\u00a0Kailos\u00a0Genetics; Other support: AstraZeneca (member, independent data monitoring committee) and Genentech\/Roche (third-party writing assistance). Eleftherios P. Mamounas: Genentech\/Roche, Exact Sciences: Consultant (Advisory Board) and Speaker\u2019s Bureau. Biotheranostics, Daiichi Sankyo, Puma Biotechnology, Merck: Consultant (Advisory Board).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}